-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On July 2, China Biopharmaceuticals issued an announcement stating that the anti-PD-1 monoclonal antibody drug "Paampril" jointly developed by the group and Kangfang Biotechnology (Cayman) Co.
A few days ago, Pianpril has passed the new real-time tumor review (RTOR) policy for the third-line treatment of metastatic nasopharyngeal carcinoma, and submitted a biologics license application (BLA) to the US FDA